# Novel Drug Approvals at FDA

## Novel Drug Approvals for 2024

9. **Voydeya**: Voydeya, which contains danicopan, was approved on March 29, 2024. It is indicated for the treatment of extravascular hemolysis with paroxysmal nocturnal hemoglobinuria.

10. **Vafseo**: Approved on March 27, 2024, Vafseo contains vadadustat and is used for the treatment of anemia due to chronic kidney disease.

11. **Winrevair**: On March 26, 2024, Winrevair, with the active ingredient sotatercept-csrk, was approved for the treatment of pulmonary arterial hypertension.

12. **Duvyzat**: Duvyzat, containing givinostat, was approved on March 21, 2024. It is indicated for the treatment of Duchenne muscular dystrophy in individuals aged 6 years and older.

13. **Tryvio**: Approved on March 19, 2024, Tryvio contains aprocitentan and is used for the treatment of hypertension.

14. **Rezdiffra**: On March 14, 2024, Rezdiffra was approved. This drug, with the active ingredient resmetirom, is used for treating noncirrhotic non-alcoholic steatohepatitis with moderate to advanced liver scarring.

15. **Tevimbra**: Approved on March 13, 2024, Tevimbra contains tislelizumab-jsgr and is indicated for the treatment of unresectable or metastatic esophageal squamous cell carcinoma.

16. **Letybo**: Letybo, with the active ingredient letibotulinumtoxinA-wlbg, was approved on February 29, 2024. It is used to temporarily improve the appearance of moderate-to-severe glabellar lines.

17. **Exblifep**: Approved on February 22, 2024, Exblifep contains cefepime and enmetazobactam and is used for treating complicated urinary tract infections.

18. **Zelsuvmi**: On January 5, 2024, Zelsuvmi, containing the active ingredient berdazimer, was approved for the treatment of molluscum contagiosum.
